-
1دورية أكاديمية
المؤلفون: Marcovecchio, M Loredana, Hendriks, A Emile J, Delfin, Carl, Battelino, Tadej, Danne, Thomas, Evans, Mark L, Johannesen, Jesper, Kaur, Simranjeet, Knip, Mikael, Overbergh, Lut, Pociot, Flemming, Todd, John A, Van der Schueren, Bart, Wicker, Linda S, Peakman, Mark, Mathieu, Chantal, INNODIA consortium
مصطلحات موضوعية: Age, Beta cell function, C-peptide, Prevention, Subgroups, Treatment, Type 1 diabetes
وصف الملف: application/pdf
العلاقة: https://www.repository.cam.ac.uk/handle/1810/365905Test; https://doi.org/10.17863/CAM.106970Test
الإتاحة: https://doi.org/10.17863/CAM.106970Test
https://www.repository.cam.ac.uk/handle/1810/365905Test -
2دورية أكاديمية
المؤلفون: Marcovecchio, M Loredana, Hendriks, A Emile J, Delfin, Carl, Battelino, Tadej, Danne, Thomas, Evans, Mark L, Johannesen, Jesper, Kaur, Simranjeet, Knip, Mikael, Overbergh, Lut, Pociot, Flemming, Todd, John A, Van der Schueren, Bart, Wicker, Linda S, Peakman, Mark, Mathieu, Chantal, INNODIA consortium
مصطلحات موضوعية: Age, Beta cell function, C-peptide, Prevention, Subgroups, Treatment, Type 1 diabetes, Humans, Diabetes Mellitus, Type 1, Adolescent, Child, Male, Female, Adult, Young Adult, Preschool, Autoantibodies, Glycated Hemoglobin, Blood Glucose, Cohort Studies, Infant, Europe, Middle Aged, Insulin-Secreting Cells
وصف الملف: application/pdf; text/xml
-
3دورية أكاديمية
المؤلفون: Wilhelm-Benartzi, Charlotte S., Miller, Sarah E., Bruggraber, Sylvaine, Picton, Diane, Wilson, Mark, Gatley, Katrina, Chhabra, Anita, Marcovecchio, M. Loredana, Hendriks, A. Emile J., Morobe, Hilde, Chmura, Piotr Jaroslaw, Bond, Simon, Aschemeier-Fuchs, Barbel, Knip, Mikael, Tree, Timothy, Overbergh, Lut, Pall, Jaivier, Arnaud, Olivier, Haller, Michael J., Nitsche, Almut, Schulte, Anke M., Mathieu, Chantal, Mander, Adrian, Dunger, David
المساهمون: HUS Children and Adolescents, Children's Hospital, Research Programs Unit, CAMM - Research Program for Clinical and Molecular Metabolism
مصطلحات موضوعية: BETA-CELL FUNCTION, RECENT-ONSET, DOUBLE-BLIND, C-PEPTIDE, THERAPY, PREVALENCE, DURATION, 3121 General medicine, internal medicine and other clinical medicine
وصف الملف: application/pdf
العلاقة: This clinical trial is funded by Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU) INNODIA under grant agreement no 115797. This Joint Undertaking receives support from the Union's Horizon 2020 research and innovation program and 'EFPIA', 'JDRF' and `The Leona M. and Harry B. Helmsley Charitable Trust'. The IMP is supplied by INNODIA member Sanofi. The CE-marked CGM devices are provided by DexCom (USA). supported by IMI2-JU under grant agreement No 115797 (INNODIA) and No 945268 (INNODIA HARVEST). DD was supported by the UK NIHR Cambridge Biomedical Research Centre.The sponsor is Universitaire Ziekenhuizen Leuven (UZL), Leuven, Belgium. Sponsor Number: S63466. Central Coordination is done on behalf of the sponsor by the University of Cambridge, UK (MELD-ATG@medschl.cam.ac.uk).The EudraCT Number is 2019-003265-17.; Wilhelm-Benartzi , C S , Miller , S E , Bruggraber , S , Picton , D , Wilson , M , Gatley , K , Chhabra , A , Marcovecchio , M L , Hendriks , A E J , Morobe , H , Chmura , P J , Bond , S , Aschemeier-Fuchs , B , Knip , M , Tree , T , Overbergh , L , Pall , J , Arnaud , O , Haller , M J , Nitsche , A , Schulte , A M , Mathieu , C , Mander , A & Dunger , D 2021 , ' Study protocol : Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes ' , BMJ Open , vol. 11 , no. 12 , 053669 . https://doi.org/10.1136/bmjopen-2021-053669Test; 2ea7f5a7-f008-4f85-a9ee-ab631f0269ab; http://hdl.handle.net/10138/338177Test; 000730060800005